Prior Reported, ESSA Pharma Presents Data on Prostate Cancer Therapy Masofaniten at ESMO 2024, Shows Prolonged PSA Reduction
Prior Reported, ESSA Pharma Presents Data on Prostate Cancer Therapy Masofaniten at ESMO 2024, Shows Prolonged PSA Reduction
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain. Masofaniten is a first-in-class N-terminal domain androgen receptor ("AR") inhibitor that suppresses androgen activity through a novel mechanism of action and is being developed for the treatment of prostate cancer. The poster presentation is available on the "Publications" section of the Company's website at .
ESSA Pharma Inc.（"ESSA"或"公司"）（納斯達克：EPIX）是一家臨床階段的藥品公司，專注於開發治療前列腺癌的新型療法。今天宣佈了其在2024年歐洲醫學腫瘤學會（ESMO）大會上發佈了Masofaniten（前稱EPI-7386）與恩扎魯胺聯合使用的劑量遞增數據，該大會將於2024年9月13日至17日在西班牙巴塞羅那舉行。Masofaniten是一種首創的N末端結域雄激素受體（"AR"）抑制劑，通過新的作用機制抑制雄激素的活性，並用於治療前列腺癌。海報展示可在公司網站的「出版物」部分找到。
"We are pleased to be sharing more mature data from the Phase 1 dose escalation study evaluating masofaniten in combination with enzalutamide today at ESMO 2024. The combination continues to be well tolerated with prolonged reductions in circulating prostate-specific antigen ("PSA") levels in patients with metastatic castration-resistant prostate cancer ("mCRPC"). After 15.2 months of follow up, neither median time to PSA progression nor radiographic progression free survival have been reached. These data compare favorably to historical data for single agent enzalutamide treatment in the mCRPC patient population," said David Parkinson, MD, President and CEO of ESSA. "We continue to focus on the enrollment of the Phase 2 dose expansion study evaluating masofaniten in combination with enzalutamide, with 33 sites activated in the US, Canada and Australia and an additional 22 sites anticipated in Europe. We look forward to providing further updates in 2025."
「我們很高興能夠在ESMO 2024上分享與enzalutamide聯合治療的masofaniten劑量遞增研究的更爲成熟的數據。該聯合治療在轉移性去勢抗藥前列腺癌（mCRPC）患者中持續耐受，並且能夠持久降低循環前列腺特異性抗原（「PSA」）水平。隨訪15.2個月後，尚未達到PSA進展的中位時間以及放射影像進展無病生存。與mCRPC患者群體中單一劑量enzalutamide治療的歷史數據相比，這些數據值得稱道，」 ESSA的總裁兼首席執行官David Parkinson博士說。「我們繼續關注在美國，加拿大和澳大利亞開展masofaniten與enzalutamide聯合治療的Phase 2劑量擴大研究的招募工作，目前已經有33個研究地點激活，並預計在歐洲還將開設22個研究地點。我們期待在2025年提供進一步的更新。」
Poster presentation details:
海報展示詳情：
Title: Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared with Enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 results and Phase 2 design
標題：口服EPI-7386（masofaniten）與恩扎盧胺（Enz）比較聯合治療轉移性去勢耐藥前列腺癌患者（mCRPC）的1/2期試驗：1期結果和2期設計
Presenting Author: Christos Kyriakopoulos, MD, University of Wisconsin-Madison Carbone Cancer Center
主講人：Christos Kyriakopoulos，MD，威斯康星大學麥迪遜分校Carbone癌症中心
Presentation #: 1641P
Date and time: Sunday, September 15, 2024; 12:00-1:30 p.m. CEST/ 6:00-7:30 a.m. ET
演示編號：1641P
日期和時間：2024年9月15日，週日；中歐夏令時間下午12:00-1:30 / 美國東部時間上午6:00-7:30
譯文內容由第三人軟體翻譯。
